Tamara Vokes to Quality of Life
This is a "connection" page, showing publications Tamara Vokes has written about Quality of Life.
Connection Strength
1.298
-
Quality of Life in Hypoparathyroidism. Endocrinol Metab Clin North Am. 2018 12; 47(4):855-864.
Score: 0.303
-
Quality of life in hypoparathyroidism. Bone. 2019 03; 120:542-547.
Score: 0.302
-
Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. J Clin Endocrinol Metab. 2018 02 01; 103(2):722-731.
Score: 0.289
-
Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism. Eur J Endocrinol. 2025 Sep 30; 193(4):428-439.
Score: 0.123
-
Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey. J Bone Miner Res. 2022 12; 37(12):2630-2641.
Score: 0.101
-
Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension. J Clin Endocrinol Metab. 2026 Mar 17; 111(4):945-952.
Score: 0.032
-
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. Eur J Endocrinol. 2025 Jul 31; 193(2):310-319.
Score: 0.030
-
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):951-960.
Score: 0.030
-
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023 01; 38(1):14-25.
Score: 0.025
-
Management of Hypoparathyroidism. J Bone Miner Res. 2022 12; 37(12):2663-2677.
Score: 0.025
-
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022 01 01; 107(1):e372-e385.
Score: 0.024
-
Presentation of Hypoparathyroidism: Etiologies and Clinical Features. J Clin Endocrinol Metab. 2016 06; 101(6):2300-12.
Score: 0.016